Sage Journals: Discover world-class research

Abstract

The introduction of genetics revolutionized the field of neurodegenerative and neuromuscular diseases and has provided considerable insight into the underlying pathomechanisms. Nevertheless, effective treatment options have been limited. This changed recently when antisense oligonucleotides (ASOs) could be translated from in vitro and experimental animal studies into clinical practice. In 2016, two ASOs were approved by the United States US Food and Drug Administration (FDA) and demonstrated remarkable efficacy in Duchenne muscular dystrophy (DMD) and spinal muscular atrophy (SMA). ASOs are synthetic single-stranded strings of nucleic acids. They selectively bind to specific premessenger ribonucleic acid (pre-mRNA)/mRNA sequences and alter protein synthesis by several mechanisms of action. Thus, apart from gene replacement, ASOs may therefore provide the most direct therapeutic strategy for influencing gene expression. In this review, we shall discuss basic mechanisms of ASO action, the role of chemical modifications needed to improve the pharmacodynamic and pharmacokinetic properties of ASOs, and we shall then focus on several ASOs developed for the treatment of neurodegenerative and neuromuscular disorders, including SMA, DMD, myotonic dystrophies, Huntington’s disease, amyotrophic lateral sclerosis and Alzheimer’s disease.

Keywords

Alzheimer’s disease amyotrophic lateral sclerosis antisense oligonucleotides Duchenne muscular dystrophy Huntington’s disease myotonic dystrophy nusinersen spinal muscular atrophy

Introduction

Substantial progress in genetics has provided considerable insights into the pathomechanisms of several neurodegenerative and neuromuscular disorders. However, the translation of this knowledge into clinical practice has been challenging, and, until recently, efficient treatment strategies were scarce. This changed in September 2016, when the United States US Food and Drug Administration (FDA) approved the new antisense oligonucleotide (ASO) eteplirsen for the treatment of Duchenne muscular dystrophy (DMD). Shortly after, in December 2016, the FDA approval followed for the ASO nusinersen for the treatment of patients with spinal muscular atrophy (SMA).

ASOs are synthetic single-stranded strings of nucleic acids that consist of only a few bases (8–50 bases, ‘oligo’). They bind complimentarily (‘antisense’) through Watson–Crick base pairing to a defined part of a nucleotide sequence of the premessenger ribonucleic acid (pre-mRNA) and mature mRNA (‘sense’) and modulate its function.¹ Thus, the treatment with ASOs may represent the highest target specificity and provide an opportunity for addressing previously inaccessible drug targets.²

The history of ASOs³ is intimately connected with the first description of ‘nuclein’ in cell nuclei by Miescher in 1869,⁴ the discovery of deoxyribonucleic acid (DNA) as hereditary material in 1944,⁵ and the molecular structure of nucleic acids.⁶ In the 30 years thereafter, intensive efforts in basic research were made, and several approaches comprising chemical modifications^7–9 as well as an automated synthesis of oligonucleotides^10,11 paved the way for a therapeutic use of nucleic acids. In 1978, Zamecnik¹² and Stephenson¹³ demonstrated that the addition of a 13-mer oligodeoxyribonucleotide that binds complementarily to Rous sarcoma virus RNA can inhibit protein expression in cell cultures. The first ASO investigated within a phase I trial was designed to target p53 transcripts in patients with acute myelogenous leukaemia.¹⁴ This was followed by the first approval of fomivirsen in 1998, an ASO for the treatment of cytomegalovirus retinitis in patients with immunodeficiency.¹⁵ In the field of neuroscience, the first ASO was used in vivo in the brain in 1993 and targeted the neuropeptide Y1 (NY1) receptor mRNA.¹⁶ By repeated injections of this ASO in the cerebral ventricle of rats, a specific inhibition of NY1 receptor expression was observed and was accompanied by behavioural alterations (e.g. anxiety). A few months later, another study reported that an ASO targeting the mRNA of N-methyl-D-aspartate receptor 1 (NMDA-R1) protein in rats selectively suppressed protein translation in vivo and prevented neurotoxic effects after cerebral ischaemia.¹⁷ These results further supported the applicability of ASOs to neurological disorders.

Depending on their chemical design and target, ASOs exhibit their effects through a diverse set of mechanisms that have been extensively discussed in previous reviews.^2,18,19 In general, with regard to their mechanism of action, ASOs can be categorized into those that promote RNA degradation and those that do not. RNA-degrading ASOs recruit endogenous enzymes such as ribonuclease H (RNase H), an enzyme that recognizes RNA–DNA heteroduplexes and cleaves the RNA strand. The binding of the ASO to its target mRNA mimics this DNA–RNA pairing. Thus, the cleavage of the target mRNA by RNase H leads to a reduction of the corresponding protein.^18,20 Other common mechanisms of ASOs for reducing the amount of protein comprise translational inhibition or alterations of RNA stability via RNA modification.¹⁸ There, ASOs pair with the target mRNA but, given their chemical design, they do not initiate mRNA degradation. For example, ASOs can bind to mRNA structures and prevent the 5’-mRNA cap formation or, alternatively, they modify the polyadenylation site to prevent mRNA translation or alter RNA stability. Moreover, ASOs can directly stick to the mRNA and sterically block the 40S and 60S ribosomal subunits from attaching or running along the mRNA transcript during translation.¹⁹ Other ASOs bind on pre-mRNA intron/exon junctions and directly modulate splicing by masking splicing enhancers and repressor sequences, skipping exons, or forcing the inclusion of otherwise alternatively spliced exons.^19,21–23 ASOs can also be designed to directly bind to microRNA (miRNA) sequences and inhibit the binding of their own target mRNA.²⁴ In addition, some ASOs bind to natural antisense transcripts (NATs). NATs are regulatory endogenous RNAs that are complementary to other endogenous RNA strands.^25–27 By various regulatory mechanisms including the direct pairing with the sense transcript, they facilitate or reduce protein expression.²⁷ Thus, the administration of an ASO that antagonizes a NAT, for example, prohibits the NAT from inhibiting their mRNA and thereby, increases the corresponding protein levels.²⁸ A summary of these basic principles is depicted in Figure 1.

Figure 1.

Schematic description of several mechanisms of action of synthetic antisense oligonucleotides.

The development of ASOs for clinical application was challenging because unmodified oligonucleotides are inherently unstable and are rapidly degraded by ubiquitously expressed endo- or exonucleases.²⁹ As such, several chemical oligonucleotide modifications were required that, in sum, increased their ability to recognize the target mRNA (target specificity), their resistance to nucleases, their plasma half-life and their distribution to tissues.^2,30 The first and most remarkable chemical alteration, often referred to as ‘first generation of oligonucleotide modification’, was the modification in the phosphate backbone.^2,18 One of the nonbridging oxygen atoms in the phosphate group was replaced by a sulfur atom, resulting in a phosphorothioate (PS) backbone.^9,19,31 The addition of sulfur enhanced their nuclease resistance and elevated their plasma protein binding, most likely owing to the increased negative charge density of the sulfur backbone.³² Apart from a better cellular uptake,³² the phosphorothioate backbone modification supports the activation of the RNase H to break down target mRNAs, a critical mechanism of action of many ASOs.² Owing to their interaction with proteins, however, first-generation ASOs generate various nonspecific side effects, such as immune stimulation and complement activation.³³ Another backbone modification comprises the substitution of the 3’ oxygen in the deoxyribose ring with a 3’ amino atom. The thiophosphoroamidates and phosphoramidates exhibit high affinity toward complementary RNA and high nuclease resistance.^2,34 However, they do not activate RNase H, a feature that makes them more suitable for nondegrading RNA manipulations, such as the modulation of splicing or translation inhibition.^2,19 A second generation of ASOs were modified on the 2’ position of the sugar moiety. The most commonly used are 2’-O-methyl (2’-O-Me) and 2’-O-methoxyethyl (2’-MOE) oligonucleotides. They probably provided the highest value in the development of ASOs owing to their resistance to nucleases and their increased binding affinity, which is mostly driven by the electronegative substituent at the 2’ position.³³ Though, the most considerable disadvantage of the 2’ modification is their restricted ability to activate RNase H.² This motivated the development of chimeric ASOs, in which a core of a PS backbone is flanked by nuclease-resistant arms consisting of 2’-O-Me or 2’-MOE oligonucleotides.³³ The resulting ‘gapmer’ enables the cleavage of the target mRNA by RNase H at the central region of the ASO, whereas the outer portions provide an increased nuclease resistance and binding affinity.^2,19,33 Other 2’ modifications comprise locked nucleic acids (LNAs), in which 4’-carbon has been tethered to the 2’-hydroxyl group. Although LNA oligonucleotides exhibit an increased nuclease resistance and binding affinity, they do not support RNase H and here, as well, a gapmer design has to be employed.³⁵ In addition, an increased hepatotoxicity has been reported for LNA ASOs.³⁶ This toxicological property can be decreased by combining the structural elements of 2’-MOE and LNA nucleosides and, thus, as reported, yielded a series of modifications. One of these comprised the 2’,4’-constrained ethyl (cEt) modification that possesses a binding affinity similar to LNA ASOs by an otherwise improved safety profile.³⁷ Other backbone modifications were developed by the implementation of a morpholine rather than a ribose ring in oligonucleotides. These ASOs, referred to as morpholino ASOs,² are resistant to nucleases and are less likely to interact with proteins owing to their neutral charge.³⁸ However, they do not activate RNase H and, therefore, are primarily used in translation arrest.² Various recently developed modifications and gapmer designs that have improved pharmacokinetic and pharmacodynamic properties of ASOs have been discussed in considerable detail in other reviews.^1,2,18,19

Although these chemical modifications have improved drug-like properties and specific mechanisms of action, the implementation of ASOs in the treatment of multiple neurological disorders is still challenging. The drugs have to overcome membrane barriers that can be regarded as one limiting step. ASOs do not efficiently cross an intact blood–brain barrier (BBB).² Both their size and charge prevent their distribution across the BBB, and several studies have shown that fewer than 1% of systemically administered oligonucleotides reach the brain.^30,39,40 Thus, efforts to achieve an efficient delivery to the central nervous system (CNS) are ongoing. One mechanism by which an ASO can cross the vascular barrier is via receptor-mediated endocytosis.⁴¹ A biotinylated ASO captured with a streptavidin-conjugated monoclonal antibody to the mouse transferrin receptor reached the brain by this mechanism.⁴² The same receptor-mediated endocytosis pathway was used to deliver nanoparticles carrying ASOs into the brain parenchyma.⁴³ Another mechanism was demonstrated by cell-penetrating peptide (CPP)-based delivery systems.⁴⁴ CPPs are 5–30 amino acids’ long, positively charged peptides that transport various macromolecules across cell membranes.^45,46 In mice, systemically delivered ASOs tagged with arginine-rich CPPs were able to cross the BBB and were thereafter widely distributed in the brain.⁴⁷ Nonetheless, owing to their different chemical properties, not all ASOs are suitable for CPP coupling. ASOs encapsulated in exosomes are also able to cross the BBB, as shown by an intravenous injection of exosomes that were transduced with short viral peptides derived from rabies virus glycoprotein.⁴⁸ Recently, other viral vectors have been developed to deliver ASOs. To date, the adeno-associated virus vector possesses the most favorable properties because of it seems to be nonpathogenic and exhibits a high carrying capacity.⁴⁹ Apart from promising research to facilitate BBB penetration after systemic, intranasal, or oral administration, most of the currently available ASOs for the treatment of neurological disorders must be applied by intracerebroventricular or intrathecal delivery. Nevertheless, ASOs may provide the most direct treatment strategy for several neurological disorders. Given their well-characterized underlying pathogenetic mechanism and mutations within single or only a few genes, the potential efficacy of ASOs in the following disorders is plausible.

Spinal muscular atrophy

Spinal muscular atrophy (SMA) is a genetic autosomal-recessive disease with a progressive degeneration of alpha motor neurons. It results in proximal spinal and bulbar muscle weakness and atrophy. Consecutive impairments of respiratory muscles often lead to respiratory failure and reduced life expectancy. With an incidence of 1:10,000, SMA is the most frequent autosomal-recessive lethal disease in children after cystic fibrosis.⁵⁰ The clinical phenotype of SMA can be classified into four different subtypes (SMA type I–IV) ranging from severe to mild depending on the age of onset and level of motor function.⁵¹ The most severe SMA type I (Werdnig–Hoffmann disease) accounts for about 60% of all cases.⁵⁰

SMA is most frequently caused by a homozygous deletion or mutation within the survival motor neuron 1 (SMN1) gene located on chromosome 5q13. Apart from these ‘5q-associated SMA types’, several other gene mutations have been observed that lead to clinically heterogeneous types of SMA.⁵² The SMN1 gene codes for the ubiquitously expressed ‘survival motor neuron’ (SMN) protein, particularly important for the functioning of alpha motor neurons.^51,53,54 Due to evolutionary gene doubling,⁵⁵ humans have one or more paralogous SMN1 gene copies, referred to as SMN2, which differ from SMN1 only by a few bases. Specifically, a cytosine-to-thymine mutation in exon 7 of the SMN2 gene leads to alternative splicing processes with the consequence that exon 7 is omitted from the majority of SMN2 transcripts. This results in a small amount (approximately 10%) of functional SMN protein expressed via the SMN2 gene.⁵¹ Though, the clinical phenotype of SMA has been proven to be influenced by the number of SMN2 copies⁵⁶ and symptom severity inversely correlates with the number of SMN2 gene copies. Specifically, the presence of more copies of SMN2 leads to an increased production of normal SMN protein and a less severe clinical phenotype.^56,57

Previous treatment options in SMA had been restricted to the clinical management of pulmonary, gastrointestinal, nutritional, and orthopaedic complications.⁵⁸ This changed with the introduction of the ASO nusinersen and its approval by the FDA in December 2016 for all 5q-associated SMA types. The approval by the European Medicines Agency followed in June 2017. The fully 2’-MOE PS antisense drug nusinersen⁵⁹ specifically binds to a sequence in intron 7 of the SMN2 pre-mRNA. The drug hereby enhances the inclusion of exon 7 in the mRNA by the inhibition of negative splicing factors, resulting in an increased amount of SMN protein.^60,61

Within an open-label phase I study,⁶² 28 patients with SMA type II or III were investigated under four ascending single-dose levels of nusinersen (6 patients each with 1, 3 and 6 mg; 10 patients with 9 mg) to test drug safety and tolerability, pharmacokinetic properties, and preliminary clinical efficacy [ClinicalTrials.gov identifiers: NCT01494701 and NCT01780246]. Beyond the fact that the drug was well tolerated, this study provided early evidence for the clinical efficacy in humans by demonstrating a dose-dependent increase in motor functioning after a single intrathecal dose. Another phase II study⁵⁹ investigated the effects of 6 or 12 mg nusinersen in 20 infants with SMA type I over a period of 2–32 months. A significant improvement in the 12 mg-dose group was observed regarding the development of motor milestones and functions, survival, and the use of permanent assisted ventilation compared with baseline or with the natural history of the disorder [ClinicalTrials.gov identifier: NCT01839656]. Of the 20 patients, 4 died during the study, but this seemed to be associated with the natural history of the disease rather than with the side-effect profile of nusinersen. Investigations of autopsied neuronal tissues in three of these four patients revealed a two- to sixfold increase in SMN2 transcripts, including exon 7, as well as an increase in SMN protein compared with that known in untreated infants with SMA. Thus, the results provided evidence for an efficient correction of the SMN2 splicing by nusinersen in humans that previously had been observed only in animals.

A recently published phase III study⁶³ [ClinicalTrials.gov identifier: NCT02193074] investigated 121 symptomatic patients with SMA type I in a randomized, double-blind, and sham-procedure controlled design, in which two thirds of the infants received 12 mg nusinersen on days 1, 15, 29 and 64, and every 4 following months afterwards. Interim analyses showed that 41% of individuals treated with nusinersen achieved clinically significant improvements in motor functions after 13 months compared with sham-procedure controls (0%). This result prompted early termination of the trial and a submission to the FDA. In the final analyses, an even higher percentage of infants (51%) achieved motor milestones in the nusinersen group compared with controls. These results were confirmed by another randomized, double-blind, sham-procedure controlled phase III study⁶⁴ [ClinicalTrials.gov identifier: NCT02292537] in 126 symptomatic patients with SMA type II and III. Significant improvements in motor functions were demonstrated in children treated with nusinersen compared with the control group, in which motor functions decreased over 15 months corresponding to the natural history of the disease. Owing to the positive interim analysis, this study was also halted. An ongoing study is evaluating the long-term safety and tolerability of nusinersen in patients with SMA who previously participated in investigational studies of this ASO [ClinicalTrials.gov identifier: NCT02594124]. An additional phase II study⁶⁵ [ClinicalTrials.gov identifier: NCT02386553] is currently investigating the effects of nusinersen in SMA patients, in whom clinical symptoms were not evident at the beginning of the study. The observation in animal studies that the earlier the SMN levels were augmented, the better the therapeutic outcome, inspired this study.^61,66 Interim analysis points to promising results: the 20 presymptomatic infants with SMA have reached motor milestones after a median of 317 days treatment. These results represent a breakthrough in the treatment of SMA type I in view of the fact that such achievements in motor functions are nearly comparable with those observed in healthy infants.

The approval of the ASO nusinersen not only represents a successful approach to the treatment of SMA, it also represents a proof of concept to successfully translate antisense technology from the bench to the clinic. Nevertheless, several caveats have to be taken into account. First, nusinersen cannot efficiently cross the BBB and has to be administered into the intrathecal space by lumbar puncture. Second, nusinersen has to be given in a standard dose of 12 mg on days 0, 14, 28, and 63 followed by repeated applications in 4-month intervals. To date, no specific side effects for nusinersen are known; but renal or hepatic dysfunctions, as well as undesirable effects on coagulation and complement or antibody activation, have to be considered, as is the case for other ASOs, especially after systemic administration.^2,30,67–69

In addition, the encouraging results of nusinersen treatment of SMA are based on clinical studies in infants. The clinical efficacy of nusinersen in adolescents or adults with less severe disease progression (e.g. SMA type III or IV) has not yet been studied. The identification of sensitive parameters to monitor drug efficacy in such individuals will pose a considerable challenge.

Despite these caveats, various genetic alterations contribute to the broad spectrum of clinical phenotypes in SMA⁵² and make concomitant targeting of several pathological mechanisms in SMA plausible.⁷⁰ However, even a combination of drugs directed at just the SMN pathway have also proven more effective than an individual treatment, as shown by an ASO that targets the SMN2-repressing long noncoding RNA (lnc-RNA).⁷¹ The lnc-RNA arises from the antisense strand of SMN (SMN-AS1) and represses SMN expression. A degradation of SMN-AS1 with ASOs increased SMN expression in patient-derived cells, cultured neurons, and the CNS in mice. Notably, when the SMN- AS1 targeting ASO was delivered in combination with SMN2 splice-switching ASOs, the SMN expression was additively increased and survival improved.

Another novel approach to the therapy of SMA goes even a step further and entails gene replacement rather than the pure alteration of gene expression. Mendell and colleagues⁷² recently reported about their open-label phase I/II study [ClinicalTrials.gov identifier: NCT02122952], in which 15 patients with SMA type I received a single dose of an intravenous nonreplicating adenovirus vector that included the normal human SMN1. The treatment was well tolerated and resulted in longer survival, superior achievement of motor milestones, and better motor functions than observed in historical cohorts. This also may reflect the start of an era of novel therapies in the field of neurology.

Duchenne muscular dystrophy

DMD is a genetic X-linked recessive muscular disease clinically characterized by progressive muscular wasting and weakness within the first years of life, and loss of the ability to walk during childhood or adolescence. Owing to respiratory failure or cardiac dysfunction, the disorder leads to death in late adolescence,^73,74 if patients are not supported by intervention strategies, such as non-invasive ventilation. DMD occurs with an incidence of 1:3500 male births and represents the most common inherited paediatric muscle disorder.^75,76 The disease is caused by mutations in the dystrophin gene located on Xp21, resulting in truncated protein or loss of transcript through nonsense-mediated decay.^2,77 Approximately 60% of dystrophin mutations are large insertions or deletions that shift the reading frame, whereas about 40% of cases are caused by point mutations.^78,79 The majority of patients with DMD lack the dystrophin protein which plays a critical structural role in skeletal and cardiac muscles. The protein links the internal cytoskeleton to the extracellular matrix as a major component of the dystrophin glycoprotein complex (DGC).^76,80 A clinically milder form has been referred to as Becker muscular dystrophy (BMD) and is caused by a reduction of the amount or alterations in the size of the dystrophin protein.⁷⁹

Previous treatment options for DMD have included nonpharmacological strategies, such as non-invasive ventilation, physiotherapy, and orthopaedic treatment. With regard to pharmacological treatment, only glucocorticoids have proved to be efficient in slowing down disease progression.⁸¹ Major efforts has been devoted to developing efficient treatment strategies in DMD, ranging from gene replacement, stem-cell therapy, and aminoglycoside antibiotics and proteasome inhibitors.⁷⁹ Similar efforts have been made to develop ASOs that promote the skipping of specific dystrophin exons.

However, given that multiple genomic alterations cause DMD, no single ASO will appropriately address all forms of the disease.² Therefore, we focus here on the two most advanced ASOs in clinical trials, drisapersen and eteplirsen, both of which promote the skipping of exon 51. In general, skipping this exon restores the reading frame of dystrophin RNA and enables the translation of a truncated dystrophin protein as opposed to no dystrophin.^2,82,83 This, in turn, has the potential to convert the severe DMD into a milder BMD phenotype.^84,85 Notably, skipping exon 51 could help most patients, that is, approximately 14% of those with DMD.⁸⁶

The ASO drisapersen is a 2’-O-Me PS oligonucleotide that selectively binds to a sequence within exon 51 to promote exon skipping.^2,83,87 An exploratory, double-blind, placebo-controlled phase II study⁸⁷ [ClinicalTrials.gov identifier: NCT01153932] has examined the safety and efficacy of drisapersen (6 mg/kg) in DMD. The ASO was administered either continuously (once weekly) or intermittently (nine doses over 10 weeks) by subcutaneous injections. After 25 weeks, significant improvement was observed for the primary endpoint (6-minute walk distance, 6MWD) when compared with baseline and with placebo in the continuously treated group. In contrast, no differences in 6MWD from baseline were observed under intermittent drisapersen administration compared with the placebo group. The most common adverse events reported were injection-site reactions and renal events, for example, subclinical proteinuria. However, the encouraging clinical effects under the continuous treatment with drisapersen compared with placebo did not reach statistical significance by week 49.^86,87 A subsequent and larger double-blind phase III study investigated 186 patients randomized to drisapersen (6 mg/kg/week) or to placebo for 48 weeks. This study confirmed the lack of significant effects on primary endpoints (6MWD) with the consequence that drisapersen failed to receive market approval.^2,86

Eteplirsen is a morpholino ASO that binds similarly to drisapersen on exon 51 of the dystrophin pre-mRNA.⁸⁸ An initial open-label study investigated six dosages of intramuscularly administered eteplirsen for safety and biochemical efficacy [ClinicalTrials.gov identifier: NCT00159250]. Elevated dystrophin expression was observed in muscle biopsies for the highest dosages (0.9 mg) along with good tolerability.^89,90 A double-blind placebo-controlled study was conducted to investigate eteplirsen’s ability to improve the distance walked in the 6MWD test.⁷⁵ Twelve DMD patients were randomized to receive 30 or 50 mg/kg/week eteplirsen by intravenous infusion or placebo. After 24 weeks of treatment, no significant improvement in the 6MWD was observed under eteplirsen compared with placebo. However, muscle biopsies revealed an increase of dystrophin-positive fibers up to 23% in the patients treated with 30 mg/kg eteplirsen, whereas no such increase was detectable in the placebo group. At week 25, patients who initially received placebo switched to an open-label treatment with either 30 or 50 mg/kg/week eteplirsen. After a further 24 weeks (48 weeks after the start of this study), subjects treated with 50 mg/kg eteplirsen revealed a stable or even increased performance in 6MWD compared with a decline in those patients initially treated with placebo. Notably, even greater increases in dystrophin-positive fibers were observed at this time point (52% and 43% in the 30 and 50 mg/kg cohort, respectively), thereby indicating that treatment duration rather than dosage may account for the beneficial effects of the drug. Finally, long-term follow-up investigations after 36 months confirmed the maintenance of ambulation in the majority of these patients.⁹¹ Eteplirsen was approved by the FDA in September 2016 for the treatment of patients with DMD and with a confirmed gene mutation that is amenable to exon 51 skipping. However, as mentioned previously, the development of efficient ASOs in DMD is challenging because multiple genomic alterations may cause this disorder. As such, ongoing research regarding the therapy of DMD with ASOs is focusing on agents that support multiexon skipping. Thus, the applicability of these ASOs may increase to up to 50–70% of DMD cases.⁹²

Myotonic dystrophies

Myotonic dystrophies (DMs) are genetic autosomal-dominant inherited multisystem diseases with phenotypic core patterns comprising distal myotonia, proximal muscular dystrophy, cardiac conduction defects, posterior iridescent cataracts and endocrine disorders, such as male hypogonadism or diabetes.⁹³ Based on their clinical phenotypes and the underlying genetic alterations, DMs can be assigned to two main subtypes. Steinert and colleagues first described in 1909 the ‘classic’ DM (now referred to as DM type 1) characterized by the clinical features described above. DM type 1 is caused by an expansion of an unstable CTG trinucleotide repeat in the 3’ untranslated region (UTR) of the myotonic dystrophy protein kinase (DMPK) gene located on chromosome 19q13.3 that codes for a myosin kinase expressed in skeletal muscle.^93–96 Much later, a milder multisystem disorder was described with predominantly proximal rather than distal muscular weakness and cataracts, but without the respective gene defect described above.^93,97–100 The pathomechanism is ascribed to an unstable tetranucleotide repeat expansion (CCTG) in intron 1 of the nucleic acid-binding protein (CNBP) gene on chromosome 3q21.^101,102 Thus, patients with the clinical pattern of predominantly proximal myotonic myopathy with a positive test for unstable CCTG-repeat expansion on chromosome 3q21 are classified as having DM type 2.¹⁰³

Although DM types 1 and 2 share some clinical phenotypes, various dissimilar symptoms distinguish them. Whereas life expectancy is reduced in DM type 1, it is within the normal range in DM type 2.⁹³ DM is the most common adult-onset muscular dystrophy, and a large-scale population study revealed that DM type 2 may even be the most common inherited muscle disease in the European population.¹⁰⁴ Taken together, the prevalence of DM types 1 and 2 is estimated at 12–20 per 100,000, with widely varying rates in different populations.^104,105

Currently, there is no cure for DM and the management in DM type 2 is similar to that in DM type 1 except for a few specific treatments. The main therapeutic options are restricted to supportive strategies: physiotherapy, assistive devices, such as wheelchairs, eye and cardiorespiratory monitoring, and the treatment of endocrinological abnormalities.⁹³ Several pharmacological treatments have been tested including mexiletine, gabapentin, nonsteroidal anti-inflammatory drugs, low-dose steroids, and tricyclic antidepressants but none of these has been effective.⁹³

However, there is increasing evidence for an effective treatment option with ASOs in DM. The mutations in DM type 1 and 2 induce mutant RNAs containing CUG or CCUG expanded repeats that are retained in the nuclei and alter alternative splicing factors, such as muscleblind-like 1 proteins (MBNL). The resulting misregulated splicing of several pre-RNAs appears to underlie most of the symptoms in DM. Based on the idea that a reduction of (CUG)n RNA dosage might be beneficial to patients, Mulders and colleagues¹⁰⁶ investigated the 2’-O-Me PS ASO (CAG)7 that silences mutant DMPK RNA expression and selectively minimizes the number of ribonuclear aggregates. In a DM type 1 mouse model, they observed a significant reduction of the level of toxic (CUG)n RNA and normalizing effects on aberrant pre-mRNA splicing as a proof of principle in vivo. Another study performed in a transgenic mouse model of DM type 1 investigated the effects of several systemically administered ASOs and also demonstrated a rapid decrease of CUG-expanded RNA in skeletal muscles by a 2’-MOE ASO along with normalized splicing and reversed myotonia. Impressively, the effect was sustained for up to 1 year after treatment discontinuation.¹⁰⁷

A further study investigated the effects of a novel high-affinity class of an ASO containing cEt modification.¹⁰⁸ The systemic delivery of this ASO to wild-type mice decreased DMPK mRNA levels by up to 90% in skeletal muscle. In transgenic mice and Cynomolgus monkey, a similar impressive inhibition of DMPK was observed in cardiac muscle (up to 50%) and multiple skeletal (up to 70%) muscles. The ASO was well tolerated and here, too, a sustained inhibition of DMPK mRNA levels in muscles was demonstrated up to 13–16 weeks post treatment. Beyond these encouraging results arising from animal studies, Ionis Pharmaceuticals Inc. has recently completed a phase I/IIa placebo-controlled study to assess safety and tolerability of multiple doses of ISIS-DMPKRx in adults with DM type 1 [ClinicalTrials.gov identifier: NCT023412011]. To date, the chimeric ASO ISIS-DMPKRx that contains both, 2’-MOE and cEt modifications was well tolerated¹⁰⁹; efficacy results will be reported in the near future.

Huntington’s disease

Huntington’s disease (HD) is a rare monogenetic neurodegenerative disorder that is clinically characterized by hyperkinetic involuntary movements, dystonia, behavioural abnormalities and cognitive decline. Clinical symptoms typically manifest between 30–50 years of age and invariably progress over time. The prevalence in the White population is estimated at 5–10 per 100,000.¹¹⁰ The autosomal dominantly inherited disease is caused by an abnormal expansion of the CAG repeat in exon 1 of the huntingtin (HTT) gene located on the short arm of chromosome 4.¹¹¹ It codes for the HTT protein that is involved in a broad range of cellular functions, including neuronal survival¹¹² and axon stability.¹¹³ CAG repeats above 40 cause the disease with full penetrance, whereas CAG repeats between 37–39 show incomplete penetrance. CAG expansions ranging from 6 to 26 repeats are considered normal. The so-called intermediate alleles, ranging between 27 and 35 CAG repeats, are instable during meiotic transmission.¹¹⁴

The mutant HTT protein harbours an expanded polyglutamine tract, which mediates toxic gain of function effects including intraneuronal aggregation or abnormal interactions with other proteins.¹¹⁵ The medium spiny neurons of the striatum are particularly vulnerable to these toxic effects. An initial loss of the indirect pathway that leads to hyperkinetic movements is followed by a loss of MSNs of the direct pathway, thereby leading to hypokinesia.¹¹⁶ The reasons for this preferential vulnerability remain speculative, although a different distribution of dopamine D2 receptor expression is thought to be involved.¹¹⁷

Whereas progress in understanding the underlying genetics in HD has been substantial since its first clinical description in 1872, no disease-modifying treatment options are available, and current medical management is restricted to supportive care. This may change with the advent of HTT-lowering ASOs. In 2012, Kordasiewicz and colleagues investigated the in vivo effects in several mouse models of a 2’-MOE PS ASO with RNase H-mediated degradation properties that targets mutant HTT mRNA. Notably, they could demonstrate that a transient infusion of the ASO into the cerebrospinal fluid of symptomatic HD mice significantly delayed disease progression and decreased HTT levels that persisted for longer than the HTT knockdown.^18,118 Transgenic human HTT mRNA could be decreased by 50–80% in most brain regions, and survival was extended even when the ASO was applied to a more severely progressing mouse model. The safety profile was excellent. However, it has to be taken into account that this ASO not only reduced the expression of mutant HTT but also that of wild-type HTT. Although the study detected no major adverse events, further research focused on increasing the specificity regarding mutant alleles. Hence, Østergaard and colleagues¹¹⁹ introduced ASOs that enhance single nucleotide discrimination up to 100-fold for mutant HTT allele over normal in patient cells and in a humanized mouse model of HD.

Despite the ongoing general debate about how well mouse models recapitulate human diseases, these studies provided proof of concept for pursuing ASO treatment in HD. Recently, a phase I/IIa clinical study to assess safety, tolerability, and the pharmacological properties of multiple ascending doses of an intrathecally applied ASO [ISIS 443139, IONIS-HTTRx; ClinicalTrials.gov identifier: NCT02519036] in patients with early-stage HD was completed. The formal publication of the results from this trial is expected during the first half of 2018, but according to an online press release, a dose-dependent reduction of HTT has been observed, along with a good safety and tolerability profile.

Amyotrophic lateral sclerosis

ALS is a severe late-onset neurodegenerative disease with a progressive dysfunction of the upper and lower motor neurons of the motor cortex and spinal cord. Clinical symptoms include fasciculations, spasticity, progressive muscle weakness, and muscle atrophy. The disease is characterized by a fatal course and, typically, death occurs within 2–4 years from the time of diagnosis, mainly due to respiratory failure.^120–122 In Europe, the incidence of ALS is estimated with 1.7–3.0 cases per 100,000,^123,124 although rates greatly differ in various parts of the world.¹²¹

The precise pathomechanisms of ALS have not been fully clarified. Substantial evidence exists for a pivotal role of phosphorylated 43-kDA Transactivating Response Region (TAR) DNA-binding protein (pTDP-43) in ALS pathology.^125,126 An aggregation and progressive accumulation of pTDP-43 in selected neurons and oligodendrocytes is thought to cause their loss of physiological function.¹²⁷ In line with the clinical spreading pattern, pTDP-43 pathology seems to disseminate by cell-to-cell transmission via axonal transport and through synaptic contacts from cortical neuronal projections to other brain regions and the spinal cord.¹²⁸

About 95% of ALS cases are believed to occur sporadically, whereas approximately 5–10% are inherited.^124,129 Several gene mutations could be associated with both sporadic (sALS) and familial (fALS) ALS.^130,131 The best studied gene associated with ALS is SOD1, located on chromosome 21q.^131,132 More than 180 mutations in this gene have been reported (http://alsod.iop.kcl.ac.uk/Overview/gene.aspx?gene_id=SOD1) and account for up to 20% of fALS and up to 2–3% of sALS cases.^133,134 SOD1 encodes copper/zinc superoxide dismutase (Cu/Zn SOD), a homodimeric metalloenzyme that binds copper and structural zinc ions and catalyses the dismutation of superoxide radicals.¹³⁵ Although the detailed mechanisms are not yet fully understood, mutant SOD1 forms are assumed to decrease conformational stability and promote misfolding of the protein.¹³⁶ For years, toxic gain of function mechanisms were considered to cause SOD-linked ALS rather than a loss of protein function.¹³² More recently, however, there is evidence that SOD1 loss of function may also play a considerable modifying role.¹³⁷ Nevertheless, the development of ASOs targeting SOD1 appeared a logical step, considering that lowering the levels of mutant SOD1 protein is predicted to slow disease progression.¹³⁸ Accordingly, a 2’-MOE PS ASO that targets SOD1 mRNA significantly reduced SOD1 protein and mRNA levels throughout the brain and the spinal cord in rats after intrathecal administration.¹³⁹ When this ASO was given prior to symptom onset, as defined by retrospective analyses in an ALS mouse model, disease progression could be delayed and survival extended.¹³⁹ A randomized, placebo-controlled phase I trial [Clinicaltrials.gov identifier: NCT01041222] investigated this ASO at increasing doses in humans with SOD1-related ALS. It demonstrated an excellent safety and tolerability profile.¹⁴⁰ Moreover, a second-generation ASO compound BIIB067 (IONIS-SOD1Rx) is entering a phase I/II trial [ClinicalTrials.gov identifier: NCT02623699] to evaluate its safety, tolerability and pharmacokinetic properties in a single-dose cohort, followed by a multiple-dose cohort in SOD1-linked ALS.

More recently, expanded hexanucleotide repeats in a chromosome 9p21 open reading frame 72 (C9orf72) were identified as the most common genetic cause of ALS that account for approximately 30% of fALS and up to 5% of sALS cases.^141,142 Specifically, a GGGGCC hexanucleotide expansion occurs between two five prime noncoding exons of C9orf72. The gene encodes an uncharacterized protein with a yet unknown function,¹⁴³ but it may have an important role in membrane trafficking and autophagy.¹⁴⁴ The underlying mechanism that mediates disease pathogenesis is not fully understood. A loss of normal C9orf72 function has been proposed and seems plausible, given the fact that impaired autophagy and endolysosomal degradation are implicated in neurodegenerative diseases.¹⁴⁵ In support of this hypothesis, an experimental knockdown of the zebrafish orthologue of C9orf72 was associated with axonopathy and motor deficits that could be rescued by expressing human C9orf72 mRNA.¹⁴⁶ In addition, a homozygous knockout of the worm orthologue of C9orf72 resulted in a degeneration of motor neurons along with motor deficits.¹⁴⁷ Despite the loss of function, two further distinct gain-of-function mechanisms have been discussed: first, the formation of repeat RNA aggregates (RNA foci) in neuronal nuclei and, second, the generation of toxic dipeptide-repeat (DPR) peptides.^127,148,149 Research on the development of efficient treatment options is a high priority because the repeat expansion in C9orf72 is a major cause of both frontotemporal dementia (FTD) and ALS.¹⁴¹

Donnelly and colleagues¹⁵⁰ investigated several ASOs that recruit RNase H or block the interaction between the repeat expansion and RNA binding proteins. They demonstrated a reduction of toxic RNA foci and restored normal gene expression markers. A suppression of several pathological features, including RNA foci and DPRs, was concordantly shown for ASOs in primary cortical neurons from mice.¹⁵¹ These results were confirmed by a recent investigation of ASOs in experimental animals¹⁵² that selectively targeted repeat-containing RNAs and also led to a rapid reduction in RNA foci and DPRs. Notably, the applied single doses of these ASOs were also accompanied by a sustained improvement of behavioural deficits. Further promising results were recently observed regarding ASOs targeting the ataxin-2 (ATNX2) gene, which is implicated in spinocerebellar ataxia type 2 and as a modifier gene in TDP-43-driven ALS. After a single administration of ASOs targeting ATNX2 into the CNS of transgenic mice, survival could be extended considerably.¹⁵³

Together with these encouraging results, other ASO strategies that have been tested in animal models (summarized in Tosolini and Sleigh¹⁵⁴) indicate that the development of ASOs in the therapy of ALS is not lagging far behind those recently approved by the FDA for SMA and DMD.

Alzheimer’s disease

Alzheimer’s disease (AD) is the most prevalent cause of dementia and represents one of the major healthcare challenges in the 21st century given that prevalence rates are thought to double every 20 years until at least 2050.¹⁵⁵ Clinical features range from progressive memory impairment and executive dysfunction to psychiatric symptoms that severely interfere with activities of daily life. Decades of research regarding the underlying pathomechanisms of AD have identified two major molecular markers, namely, the accumulation of the abnormally folded amyloid beta peptide (Aβ) and tau proteins in amyloid plaques and neurofibrillary tangles.^156,157

Aβ-pathologies are associated with intracellular processing of the amyloid precursor protein (APP), a transmembrane protein with cleavage sites for alpha- (α-), β- and gamma- (γ-)secretases. The cleavage of APP directly by α- and then γ-secretases typically does not generate Aβ or lead to its reinternalization in endosomal compartments.¹⁵⁸ However, when APP is cleaved by β- and γ-secretases, the resulting Aβ-fragment oligomerizes to insoluble fibrils and plaques¹⁸ that cause toxicity through several mechanisms, including microglial infiltration, the generation of reactive oxygen species and synaptic damage.¹⁵⁸ Several APP mutations have been identified in early-onset, autosomal dominant, fully penetrant AD.¹⁵⁸

An early study¹⁵⁹ investigated the effects of phosphorothioate-modified ASOs targeting the A region of the APP gene, on reversing elevated APP levels and behavioural impairments in mice. Three intracerebroventricular injections of the ASO reduced APP levels by 43–68% in specific brain regions along with improvement in learning and of memory deficits. Subsequently, an intravenously administered APP targeting ASO was investigated in mice and confirmed a significant reduction of AβPP-signal along with decreased neuroinflammation by otherwise improved learning and memory.⁴⁰ However, the poor ability of this ASO to cross the BBB and the restricted transferability attributable to the use of specific mouse models represent considerable limitations, and have delayed the advancement of ASOs targeting APP.¹⁸

Genetic components have not only been associated with early but also with late-onset sporadic disease forms. In detail, the apolipoprotein isoform ApoE-ε4 confers a 2- to 12-fold risk for the development of AD in humans.¹⁶⁰ The development of ASOs that target the apolipoprotein E receptor 2 (ApoER2) seems intuitive, inasmuch as the receptor modulates APP localization and the processing that results in an increased Aβ production.¹⁶¹ Physiological ApoER2 signalling requires amino acids that are encoded by an alternatively spliced exon 18 in humans (exon 19 in mice), and a deregulated splicing mechanism could be demonstrated in AD. Hence, Hinrich and colleagues¹⁶² investigated an ASO that increases exon 19 splicing in mice and observed that a single dose corrected ApoER2 splicing for up to 6 months along with a potential improvement in synaptic function, memory, and learning.

A pivotal role in the pathogenesis of AD but also in other neurodegenerative disorders has been ascribed to tau proteins. The microtubule-associated protein tau is physiologically involved in the stabilization of microtubules, in intracellular signaling, and in neurogenesis.¹⁶³ The human brain typically expresses six isoforms of tau protein derived from a single tau (MAPT) gene. The isoforms differ based on alternative splicing within the N terminus and a repeat domain region of the tau MAPT gene.¹⁸ An exclusion of exon 10 results in splicing products expressing tau with three microtubule-binding repeats (MTBRs), while the inclusion of an imperfect repeat region encoding exon 10 leads to the expression of tau containing four MTBRs.¹⁶⁴ Whereas normal human brain typically expresses approximately equal levels of tau protein with three and four MTBRs, an alteration of this ratio has been observed in several tauopathies.¹⁶⁵ In addition, other abnormal post-translational modifications, such as tau protein hyperphosphorylation, are crucial to the early pathogenesis and neuronal death in AD.^157,164

When it is taken into consideration that the accumulation of hyperphosphorylated tau protein is directly associated with cognitive decline in AD,¹⁶⁶ a lowering of tau expression by ASOs could provide at least one therapeutic strategy. A recently conducted study investigated the effects of an ASO that selectively decreased human tau mRNA and protein in a mouse model of tauopathies.¹⁶⁷ Overall, the authors observed a decreased burden of phosphorylated tau, of hippocampal volume loss, and of neuronal death accompanied by an extended survival in experimental animals, including nonhuman primates. Another treatment strategy with ASOs in AD focuses on MAPT mutations that alter splicing processes of exon 10. A recent study demonstrated an efficient exon 10 skipping by a 2’-MOE phosphothioate ASO to bias towards a tau protein containing three MTBRs. In two mouse models expressing human tau, the ASO lowered tau containing four MTBRs without changing the total amount of tau protein.^18,168

The advantage of the specific reduction of tau protein with four MTBRs lies in its selectivity and leaves the total amount of tau unaltered. Otherwise, decreasing the total amount of tau protein by ASOs represents a substantial therapeutic approach potentially applicable for other tauopathies, such as corticobasal degeneration, progressive supranuclear palsy, argyrophilic grain disease, frontotemporal dementia with parkinsonism, and Pick’s disease. Ionis Pharmaceutials Inc. is currently conducting a phase I/II study to assess the safety and tolerability as well as the pharmacological properties of an intrathecally administered 2’MOE ASO [ISIS 814907; IONIS MAPTRx; ClinicalTrials.gov identifier: NCT03186989] in patients with mild AD. This ASO targets MAPT mRNA to decrease the amount of tau protein irrespective of its isoform.

Costs, cost effectiveness and ethical implications

Parallel to the remarkable progress in the development of ASOs, there is an ongoing debate regarding the cost-effectiveness ratio and ethical implications. For eteplirsen, the costs were estimated at US$57,600 per month despite the doubts whether the small increases of dystrophin could affect clinical progression of DMD.^169,170 Considering the price of US$125,000 per one injection of nusinersen, costs of the treatment of patients with SMA with this ASO amounts to US$750,000 for the first year and US$375,000 for every year afterwards.¹⁷¹ The currently high prices will be impossible to bear by any healthcare system and some national insurers already declined¹⁷⁰ or restricted the covering of the costs, for example, to patients with infantile-onset SMA type 1.¹⁷¹ Notably, data on long-term evidence of cost effectiveness are still missing and formal clinical but also economic impact analyses after 1–2 years of treatment may pose only one considerable approach. Moreover, the high costs raise the questions about patients that live in underinsured parts of the world and how they may have access to these drugs. Thus, global and cohesive strategies have still to be developed together with physicians, health insurers, pharmaceutical companies and policymakers.

Conclusion

At 25 years after ASOs were first used in vivo in the brain, several specific ASOs are now available or are being tested in clinical trials for the treatment of a variety of neurodegenerative disorders. In September 2016, the FDA approved the ASO eteplirsen for the treatment of DMD. Only a few months later, in December of the same year, FDA approval followed for the ASO nusinersen for SMA. Together, these developments emphasize the therapeutic potential of ASOs in the treatment of neurodegenerative disorders and prove that ASO strategies can be transferred from the bench into clinical practice. As summarized in this review, efficient ASOs are under development or have already been tested in clinical trials for the treatment of MD, HD, ALS, and AD. Beyond their encouraging results, new efficient ASOs may be anticipated in peripheral neurodegenerative disorders. A recent study¹⁷² reported the effects of an ASO for the treatment of the inherited peripheral nerve disorder Charcot-Marie-Tooth disease and demonstrated an improved myelination, even when treatment was started after symptom onset.

In summary, the advent of ASOs represents a therapeutic milestone for several neurological disorders. This was barely conceivable a few years ago. Although ASOs exhibit excellent safety and tolerability profiles, further improvements are required. Most ASOs have to be delivered directly into the intrathecal space. Not surprisingly, there is an ongoing debate regarding the cost effectiveness of these drugs.¹⁷¹ However, the SMA success story demonstrated that ASOs are effective and safe; they may even succeed in revolutionizing the entire field of therapeutic strategies in neurology.

Footnotes

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Conflict of interest statement

The authors declare the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: CDW received travel expenses for attending a meeting sponsored by Biogen and she cooperates with Hoffmann-La Roche. ACL received financial research support from AB Science, Biogen Idec, Cytokinetics, GSK, Orion Pharam, Novartis, TauRx Therapeutics Ltd. and TEVA Pharmaceuticals. He also has received honoraria as a consultant from Mitsubishi, Orion Pharma, Novartis, Teva and as an advisory board member of Biogen, Treeway, and Hoffmann-La Roche.

References

Evers

Toonen

Van Roon-Mom

. Antisense oligonucleotides in therapy for neurodegenerative disorders. Adv Drug Deliv Rev 2015; 87: 90–103.

Bennett

Baker

Pham

et al . Pharmacology of Antisense Drugs. Annu Rev Pharmacol Toxicol 2017; 57: 81–105.

Lundin

Gissberg

Smith

. Oligonucleotide therapies: the past and the present. Hum Gene Ther 2015; 26: 475–485.

Miescher

. Letter I; to Wilhelm His; Tübingen, February 26th, 1869. In: His

et al . (eds) Die histochemischen und physiologischen arbeiten von Friedrich Miescher - aus dem wissenschaftlichen Briefwechsel von F. Miescher, Vol. 1. Leipzig, Germany: FCW Vogel, 1869, pp.33–38.

Avery

MacLeod

McCarty

. Studies on the chemical nature of the substance inducing trnasformation of Pneumococcal types: induction of transformation by a desoxyribonucleic acid fraction isolated from Pneumococcus type III. J Exp Med 1944; 79: 137–158.

Watson

Crick

FHC

. Molecular structure of nucleic acids. Nature 1953; 171: 737–738.

Reist

Benitez

Goodman

. The synthesis of some 5′-thiopentofuranosylpyrimidines. J Org Chem 1964; 29: 554–558.

Codington

Doerr

Fox

. Nucleosides. XVIII. synthesis of 2′-fluorothymidine, 2′-fluorodeoxyuridine, and other 2′-halogeno-2′-deoxy nucleosides. J Org Chem 1964; 29: 558–564.

Eckstein

. Nucleoside phosphorothioates. J Am Chem Soc 1970; 92: 4718–4723.

10.

Sinha

Biernat

Mcmanus

et al . Polymer support oligonucleotide synthesis XVIII1.2: use of β-cyanoethyi-N,N-dialkylamino-/N-morpholino phosphoramidite of deoxynucleosides for the synthesis of DNA fragments simplifying deprotection and isolation of the final product. Nucleic Acids Res 1984; 12: 4539–4557.

11.

Usman

Ogilvie

Jiang

et al . Automated chemical synthesis of long oligoribonucleotides using 2’-O-silylated ribonucleoside s’-O-phosphoramidites on a controlled-pore glass support: synthesis of a 43-nucleotide sequence similar to the 3’-half molecule of an Escherichia Coli formylmeth. J Am Chem Soc 1987; 109: 7845–7854.

12.

Zamecnik

Stephenson

. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA 1978; 75: 280–284.

13.

Stephenson

Zamecnik

. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc Natl Acad Sci USA 1978; 75: 285–288.

14.

Bayever

Iversen

Bishop

et al . Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a phase I trial. Antisense Res Dev 1993; 3: 383–390.

15.

Marwick

. First ‘antisense’ drug will treat CMV retinitis. JAMA 1998; 280: 871.

16.

Wahlestedt

Pich

Koob

et al . Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides. Science 1993; 259: 528–531.

17.

Wahlestedt

Golanov

Yamamoto

et al . Antisense oligodeoxynucleotides to NMDA-R1 receptor channel protect cortical neurons from excitotoxicity and reduce focal ischaemic infarctions. Nature 1993; 363: 260–263.

18.

Schoch

Miller

. Antisense oligonucleotides: translation from mouse models to human neurodegenerative diseases. Neuron 2017; 94: 1056–1070.

19.

DeVos

Miller

. Antisense oligonucleotides: treating neurodegeneration at the level of RNA. Neurotherapeutics 2013; 10: 486–497.

20.

Cerritelli

Crouch

. Ribonuclease H: the enzymes in eukaryotes. FEBS J 2009; 276: 1494–1505.

21.

Sazani

Gemignani

Kang

et al . Systemically delivered antisense oligomers upregulate gene expression in mouse tissues. Nat Biotechnol 2002; 20: 1228–1233.

22.

Dominski

Kole

. Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides. Proc Natl Acad Sci USA 1993; 90: 8673–8677.

23.

Roberts

Palma

Sazani

et al . Efficient and persistent splice switching by systemically delivered LNA oligonucleotides in mice. Mol Ther 2006; 14: 471–475.

24.

Davis

Propp

Freier

et al . Potent inhibition of microRNA in vivo without degradation. Nucleic Acids Res 2009; 37: 70–77.

25.

Wight

Werner

. The functions of natural antisense transcripts. Essays Biochem 2013; 54: 91–101.

26.

Khorkova

Myers

Hsiao

et al . Natural antisense transcripts. Human Molecular Genetics 2014; 23: R54.

27.

Piatek

Henderson

Zynad

et al . Natural antisense transcription from a comparative perspective. Genomics 2016; 108: 56–63.

28.

Modarresi

Faghihi

Lopez-Toledano

et al . Inhibition of natural antisense transcripts in vivo results in gene-specific transcriptional upregulation. Nat Biotechnol 2012; 30: 453–459.

29.

Dagle

Weeks

Walder

. Pathways of degradation and mechanism of action of antisense oligonucleotides in Xenopus laevis embryos. Antisense Res Dev 1991; 1: 11–20.

30.

Khorkova

Wahlestedt

. Oligonucleotide therapies for disorders of the nervous system. Nat Biotechnol 2017; 35: 249–263.

31.

Stein

Subasinghe

Shinozuka

et al . Physicochemical properties of phosphorothioate oligodeoxynucleotides. Nucleic Acids Res 1988; 16: 3209–3221.

32.

Juliano

. The delivery of therapeutic oligonucleotides. Nucleic Acids Research 2016; 44: 6518–6548.

33.

Mansoor

Melendez

. Advances in antisense oligonucleotide development for target identification, validation, and as novel therapeutics. Gene Regulation and Systems Biology 2008; 2008: 275–295.

34.

Gryaznov

. Oligonucleotide n3′→p5′ phosphoramidates and thio-phoshoramidates as potential therapeutic agents. Chem Biodivers 2010; 7: 477–493.

35.

Kurreck

. Design of antisense oligonucleotides stabilized by locked nucleic acids. Nucleic Acids Res 2002; 30: 1911–1918.

36.

Swayze

Siwkowski

Wancewicz

et al . Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals. Nucleic Acids Res 2007; 35: 687–700.

37.

Seth

Siwkowski

Allerson

et al . Design, synthesis and evaluation of constrained methoxyethyl (cMOE) and constrained ethyl (cEt) nucleoside analogs. Nucleic Acids Symp Ser 2008; 52: 553–554.

38.

Geary

Norris

et al . Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Advanced Drug Delivery Reviews 2015; 87: 46–51.

39.

Banks

Farr

Butt

et al . Delivery across the blood-brain barrier of antisense directed against amyloid beta: reversal of learning and memory deficits in mice overexpressing amyloid precursor protein. J Pharmacol Exp Ther 2001; 297: 1113–1121.

40.

Farr

Erickson

Niehoff

et al . Central and peripheral administration of antisense oligonucleotide targeting amyloid-β protein precursor improves learning and memory and reduces neuroinflammatory cytokines in Tg2576 (AβPPswe) mice. J Alzheimer’s Dis 2014; 40: 1005–1016.

41.

Pardridge

. Blood-brain barrier delivery. Drug Discov Today 2007; 12: 54–61.

42.

Lee

Boado

Braasch

et al . Imaging gene expression in the brain in vivo in a transgenic mouse model of Huntington’s disease with an antisense radiopharmaceutical and drug-targeting technology. J Nucl Med 2002; 43: 948–956.

43.

Kozlu

Caban

Yerlikaya

et al . An aquaporin 4 antisense oligonucleotide loaded, brain targeted nanoparticulate system design. Pharmazie 2014; 69: 340–345.

44.

Derossi

Joliot

Chassaing

et al . The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem 1994; 269: 10444–10450.

45.

El-Andaloussi

Holm

Langel

et al . Cell-penetrating peptides: mechanisms and applications. Curr Pharm Des 2005; 11: 3597–3611.

46.

Lehto

Kurrikoff

Langel

. Cell-penetrating peptides for the delivery of nucleic acids. Expert Opin Drug Deliv 2012; 9: 823–836.

47.

Kayali

Bertoni

et al . Arginine-rich cell-penetrating peptide dramatically enhances AMO-mediated ATM aberrant splicing correction and enables delivery to brain and cerebellum. Hum Mol Genet 2011; 20: 3151–3160.

48.

Kumar

McBride

et al . Transvascular delivery of small interfering RNA to the central nervous system. Nature 2007; 448: 39–43.

49.

Phillips

. Antisense inhibition and adeno-associated viral vector delivery for reducing hypertension. Hypertension 1997; 29: 177–187.

50.

Verhaart

IEC

Robertson

Wilson

et al . Prevalence, incidence and carrier frequency of 5q–linked spinal muscular atrophy – a literature review. Orphanet J Rare Dis 2017; 12: 124.

51.

Lunn

Wang

. Spinal muscular atrophy. Lancet 2008; 371: 2120–2133.

52.

Farrar

Kiernan

. The genetics of spinal muscular atrophy: progress and challenges. Neurotherapeutics 2014; 12: 290–302.

53.

Melki

Abdelhak

Sheth

et al . Gene for chronic proximal spinal muscular atrophies maps to chromosome 5q. Nature 1990; 344: 767–768.

54.

Brzustowicz

Lehner

Castilla

et al . Genetic mapping of chronic childhood-onset spinal muscular atrophy to chromosome 5q11.2-13.3. Nature 1990; 344: 540–541.

55.

Lefebvre

Burglen

Reboullet

et al . Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995; 80: 155–165.

56.

Wirth

Brichta

Schrank

et al . Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number. Hum Genet 2006; 119: 422–428.

57.

Feldkötter

Schwarzer

Wirth

et al . Quantitative analyses of SMN1 and SMN2 based on real-time lightcycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet 2002; 70: 358–368.

58.

Castro

Iannaccone

. Spinal muscular atrophy: therapeutic strategies. Curr Treat Options Neurol 2014; 16: 316.

59.

Finkel

Chiriboga

Vajsar

et al . Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet 2016; 388: 3017–3026.

60.

Passini

Richards

et al . Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci Transl Med 2011; 3: 72ra18.

61.

Hua

Sahashi

Hung

et al . Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev 2010; 24: 1634–1644.

62.

Chiriboga

Swoboda

Darras

et al . Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy. Neurology 2016; 86: 890–897.

63.

Finkel

Mercuri

Darras

et al . Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med 2017; 377: 1723–1732.

64.

Mercuri

Finkel

Kirschner

et al . Efficacy and safety of nusinersen in children with later-onset spinal muscular atrophy (SMA): end of study results from the phase 3 CHERISH study. Neuromuscul Disord 2017; 27: S210.

65.

Bertini

Hwu

Reyna

et al . Efficacy and safety of nusinersen in infants with presymptomatic spinal muscular atrophy (SMA): interim results from the NURTURE study. Eur J Paediatr Neurol 2017; 21: e14.

66.

Zhou

Meng

Marrosu

et al . Repeated low doses of morpholino antisense oligomer: an intermediate mouse model of spinal muscular atrophy to explore the window of therapeutic response. Hum Mol Genet 2015; 24: 6265–6277.

67.

Henry

Seguin

Cavagnaro

et al . Considerations for the characterization and interpretation of results related to alternative complement activation in monkeys associated with oligonucleotide-based therapeutics. Nucleic Acid Ther 2016; 26: 210–215.

68.

Henry

Giclas

Leeds

et al . Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action. J Pharmacol Exp Ther 1997; 281: 810–816.

69.

Sheehan

Phan

. Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex by an allosteric mechanism. Biochemistry 2001; 40: 4980–4989.

70.

Bowerman

Becker

Yáñez-Muñoz

et al . Therapeutic strategies for spinal muscular atrophy: SMN and beyond. Dis Model Mech 2017; 10: 943–954.

71.

D’Ydewalle

Ramos

Pyles

et al . The antisense transcript SMN-AS1 regulates SMN expression and is a novel therapeutic target for spinal muscular atrophy. Neuron 2017; 93: 66–79.

72.

Mendell

Al-Zaidy

Shell

et al . Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med 2017; 377: 1713–1722.

73.

Mendell

Shilling

Leslie

et al . Evidence-based path to newborn screening for duchenne muscular dystrophy. Ann Neurol 2012; 71: 304–313.

74.

Bushby

Finkel

Birnkrant

et al . Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 2010; 9: 77–93.

75.

Mendell

Rodino-Klapac

Sahenk

et al . Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol 2013; 74: 637–647.

76.

Sienkiewicz

Kulak

Okurowska-Zawada

et al . Duchenne muscular dystrophy: current cell therapies. Ther Adv Neurol Disord 2015; 8: 166–177.

77.

Flanigan

. Duchenne and Becker muscular dystrophies. Neurologic Clinics 2014; 32: 671–688.

78.

Hoffman

Dressman

. Molecular pathophysiology and targeted therapeutics for muscular dystrophy. Trends in Pharmacological Sciences 2001; 22: 465–470.

79.

Nowak

Davies

. Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment. EMBO Rep 2004; 5: 872–876.

80.

Braun

Wang

Mack

et al . Gene therapy for inherited muscle diseases: where genetics meets rehabilitation medicine. Am J Phys Med Rehabil 2014; 93: S97–S107.

81.

Ricotti

Ridout

Scott

et al . Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy. J Neurol Neurosurg Psychiatry 2013; 84: 698–705.

82.

Alter

Lou

Rabinowitz

et al . Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med 2006; 12: 175–177.

83.

Aartsma-Rus

Janson

Kaman

et al . Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients. Hum Mol Genet 2003; 12: 907–914.

84.

Van Deutekom

JCT

. Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. Hum Mol Genet 2001; 10: 1547–1554.

85.

Heemskerk

De Winter

De Kimpe

et al . In vivo comparison of 2′-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping. J Gene Med 2009; 11: 257–266.

86.

Kole

Krieg

. Exon skipping therapy for Duchenne muscular dystrophy. Advanced Drug Delivery Reviews 2015; 87: 104–107.

87.

Voit

Topaloglu

Straub

et al . Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study. Lancet Neurol 2014; 13: 987–996.

88.

Arechavala-Gomeza

Graham

Popplewell

et al . Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle. Hum Gene Ther 2007; 18: 798–810.

89.

Kinali

Arechavala-Gomeza

Feng

et al . Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol 2009; 8: 918–928.

90.

Cirak

Feng

Anthony

et al . Restoration of the dystrophin-associated glycoprotein complex after exon skipping therapy in Duchenne muscular dystrophy. Mol Ther 2012; 20: 462–467.

91.

Mendell

Goemans

Lowes

et al . Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Ann Neurol 2016; 79: 257–271.

92.

Aartsma-Rus

Janson

van Ommen

G-JB

et al . Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy. BMC Med Genet 2007; 8: 43.

93.

Meola

Cardani

. Myotonic dystrophies: an update on clinical aspects, genetic, pathology, and molecular pathomechanisms. Biochim Biophys Acta 2015; 1852: 594–606.

94.

Brook

McCurrach

Harley

et al . Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3′ end of a transcript encoding a protein kinase family member. Cell 1992; 68: 799–808.

95.

Pizzuti

Fenwick

et al . An unstable triplet repeat in a gene related to myotonic muscular dystrophy. Science 1992; 255: 1256–1258.

96.

Mahadevan

Tsilfidis

Sabourin

et al . Myotonic dystrophy mutation: an unstable CTG repeat in the 3′ untranslated region of the gene. Science 1992; 255: 1253–1255.

97.

Meola

Sansone

Radice

et al . A family with an unusual myotonic and myopathic phenotype and no CTG expansion (proximal myotonic myopathy syndrome): a challenge for future molecular studies. Neuromuscul Disord 1996; 6: 143–150.

98.

Ricker

Koch

Lehmann-Horn

et al . Proximal myotonic myopathy: a new dominant disorder with myotonia, muscle weakness, and cataracts. Neurology 1994; 44: 1448–1452.

99.

Thornton

Griggs

Moxley

. Myotonic dystrophy with no trinucleotide repeat expansion. Ann Neurol 1994; 35: 269–272.

100.

Udd

Krahe

Wallgren-Pettersson

et al . Proximal myotonic dystrophy - a family with autosomal dominant muscular dystrophy, cataracts, hearing loss and hypogonadism: heterogeneity of proximal myotonic syndromes? Neuromuscul Disord 1997; 7: 217–228.

101.

Ranum

Rasmussen

Benzow

et al . Genetic mapping of a second myotonic dystrophy locus. Nat Genet 1998; 19: 196–198.

102.

Liquori

. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 2001; 293: 864–867.

103.

Day

Ricker

Jacobsen

et al . Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum. Neurology 2003; 60: 657–664.

104.

Suominen

Bachinski

Auvinen

et al . Population frequency of myotonic dystrophy: higher than expected frequency of myotonic dystrophy type 2 (DM2) mutation in Finland. Eur J Hum Genet 2011; 19: 776–782.

105.

Udd

Krahe

. The myotonic dystrophies: molecular, clinical, and therapeutic challenges. Lancet Neurol 2012; 11: 891–905.

106.

Mulders

Van den Broek

Wheeler

et al . Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy. Proc Natl Acad Sci USA 2009; 106: 13915–13920.

107.

Wheeler

Leger

Pandey

et al . Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature 2012; 488: 111–115.

108.

Pandey

Wheeler

Justice

et al . Identification and characterization of modified antisense oligonucleotides targeting DMPK in mice and nonhuman primates for the treatment of myotonic dystrophy type 1. J Pharmacol Exp Ther 2015; 355: 329–340.

109.

Thornton

Moxley

Day

et al . Study design of a phase 1/2a trial with ISIS-DMPKRx for the treatment of myotonic dystrophy type 1 (P3.167). Neurology; 86.

110.

Roos

. Huntington’s disease: a clinical review. Orphanet J Rare Dis 2010; 5: 40.

111.

McColgan

Tabrizi

. Huntington’s disease: a clinical review. Eur J Neurol. Epub ahead of print 22 September 2017. DOI: 10.1111/ene.13413.

112.

Rigamonti

Bauer

De-Fraja

et al . Wild-type huntingtin protects from apoptosis upstream of caspase-3. J Neurosci 2000; 20: 3705–3713.

113.

Dragatsis

Levine

Zeitlin

. Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat Genet 2000; 26: 300–306.

114.

Bates

Dorsey

Gusella

et al . Huntington disease. Nat Rev Dis Primers 2015; 1: 15005.

115.

Rubinsztein

. Lessons from animal models of Huntington’s disease. Trends Genet 2002; 18: 202–209.

116.

Plotkin

Surmeier

. Corticostriatal synaptic adaptations in Huntington’s disease. Curr Opin Neurobiol 2015; 33: 53–62.

117.

Deyts

Galan-Rodriguez

Martin

et al . Dopamine D2 receptor stimulation potentiates PolyQ-Huntingtin-induced mouse striatal neuron dysfunctions via Rho/ROCK-II activation. PLoS One 2009; 4: e8287.

118.

Kordasiewicz

Stanek

Wancewicz

et al . Sustained therapeutic reversal of huntington’s disease by transient repression of huntingtin synthesis. Neuron 2012; 74: 1031–1044.

119.

Østergaard

Southwell

Kordasiewicz

et al . Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS. Nucleic Acids Res 2013; 41: 9634–9650.

120.

Rowland

Shneider

. Amyotrophic lateral sclerosis. N Engl J Med 2001; 344: 1688–1700.

121.

Zarei

Carr

Reiley

et al . A comprehensive review of amyotrophic lateral sclerosis. Surg Neurol Int 2015; 6: 171.

122.

Brettschneider

Arai

Del Tredici

et al . TDP-43 pathology and neuronal loss in amyotrophic lateral sclerosis spinal cord. Acta Neuropathol 2014; 128: 423–437.

123.

Logroscino

Traynor

Hardiman

et al . Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry 2010; 81: 385–390.

124.

Rosenbohm

Peter

Erhardt

et al . Epidemiology of amyotrophic lateral sclerosis in Southern Germany. J Neurol 2017; 264: 749–757.

125.

Neumann

Sampathu

Kwong

et al . Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006; 314: 130–133.

126.

Brettschneider

Del Tredici

Toledo

et al . Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol 2013; 74: 20–38.

127.

Lee

Trojanowski

. Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration. Nat Rev Neurosci 2011; 13: 38–50.

128.

Braak

Brettschneider

Ludolph

et al . Amyotrophic lateral sclerosis—a model of corticofugal axonal spread. Nat Rev Neurol 2013; 9: 708–714.

129.

Majoor-Krakauer

Willems

Hofman

. Genetic epidemiology of amyotrophic lateral sclerosis. Clin Genet 2003; 63: 83–101.

130.

Renton

Chiò

Traynor

. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci 2014; 17: 17–23.

131.

Rosen

Siddique

Patterson

et al . Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993; 362: 59–62.

132.

Chen

Watson

Morsch

et al . Improving the delivery of SOD1 antisense oligonucleotides to motor neurons using calcium phosphate-lipid nanoparticles. Front Neurosci 2017; 11: 476.

133.

Ajroud-Driss

Siddique

. Sporadic and hereditary amyotrophic lateral sclerosis (ALS). Biochim Biophys Acta 2015; 1852: 679–684.

134.

Andersen

Al-Chalabi

. Clinical genetics of amyotrophic lateral sclerosis: what do we really know? Nat Rev Neurol 2011; 7: 603–615.

135.

Perry

JJP

Shin

Getzoff

et al . The structural biochemistry of the superoxide dismutases. Biochim Biophys Acta 2010; 1804: 245–262.

136.

Bosco

Morfini

Karabacak

et al . Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. Nat Neurosci 2010; 13: 1396–1403.

137.

Saccon

Bunton-Stasyshyn

RKA

Fisher

EMC

et al . Is SOD1 loss of function involved in amyotrophic lateral sclerosis? Brain 2013; 136: 2342–2358.

138.

Rothstein

. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann Neurol 2009; 65(Suppl. 1): S3–S9.

139.

Smith

Miller

Yamanaka

et al . Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest 2006; 116: 2290–2296.

140.

Miller

Pestronk

David

et al . An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol 2013; 12: 435–442.

141.

DeJesus-Hernandez

Mackenzie

Boeve

et al . Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011; 72: 245–256.

142.

Renton

Majounie

Waite

et al . A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011; 72: 257–268.

143.

Van Blitterswijk

DeJesus-Hernandez

Rademakers

. How do C9ORF72 repeat expansions cause amyotrophic lateral sclerosis and frontotemporal dementia: can we learn from other noncoding repeat expansion disorders? Curr Opin Neurol 2012; 25: 689–700.

144.

Nassif

Woehlbier

Manque

. The enigmatic role of C9ORF72 in autophagy. Front Neurosci 2017; 11: 442.

145.

Nixon

. The role of autophagy in neurodegenerative disease. Nat Med 2013; 19: 983–997.

146.

Ciura

Lattante

Le Ber

et al . Loss of function of C9orf72 causes motor deficits in a zebrafish model of amyotrophic lateral sclerosis. Ann Neurol 2013; 74: 180–187.

147.

Therrien

Rouleau

Dion

et al . Deletion of C9ORF72 results in motor neuron degeneration and stress sensitivity in C. elegans. PLoS One 2013; 8: e83450.

148.

Ling

Polymenidou

Cleveland

. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron 2013; 79: 416–438.

149.

Mizielinska

Isaacs

. C9orf72 amyotrophic lateral sclerosis and frontotemporal dementia. Curr Opin Neurol 2014; 27: 515–523.

150.

Donnelly

Zhang

Pham

et al . RNA Toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron 2013; 80: 415–428.

151.

O’Rourke

Bogdanik

Yanez

et al . C9orf72 is required for proper macrophage and microglial function in mice. Science 2016; 351: 1324–1329.

152.

Jiang

Zhu

Gendron

et al . Gain of toxicity from ALS/FTD-linked repeat expansions in C9ORF72 is alleviated by antisense oligonucleotides targeting GGGGCC-containing RNAs. Neuron 2016; 90: 535–550.

153.

Becker

Huang

Bieri

et al . Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature 2017; 544: 367–371.

154.

Tosolini

Sleigh

. Motor neuron gene therapy: lessons from spinal muscular atrophy for amyotrophic lateral sclerosis. Front Mol Neurosci 2017; 10: 405.

155.

Prince

Bryce

Albanese

et al . The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement 2013; 9: 63–75.e2.

156.

Scheltens

Blennow

Breteler

MMB

et al . Alzheimer’s disease. Lancet 2016; 388: 505–517.

157.

Braak

Tredici

. Neuroanatomy and pathology of sporadic Alzheimer’s disease. Switzerland: Springer International Publishing, 2015; 1–162.

158.

O’Brien

Wong

. Amyloid precursor protein processing and Alzheimer’s disease. Annu Rev Neurosci 2011; 34: 185–204.

159.

Kumar

Farr

Flood

et al . Site-directed antisense oligonucleotide decreases the expression of amyloid precursor protein and reverses deficits in learning and memory in aged SAMP8 mice. Peptides 2000; 21: 1769–1775.

160.

Corder

Saunders

Strittmatter

et al . Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 1993; 261: 921–923.

161.

Cooley

Chung

CHY

et al . Apolipoprotein receptor 2 and X11 alpha/beta mediate apolipoprotein E-induced endocytosis of amyloid-beta precursor protein and beta-secretase, leading to amyloid-beta production. J Neurosci 2007; 27: 4052–4060.

162.

Hinrich

Jodelka

Chang

et al . Therapeutic correction of ApoER2 splicing in Alzheimer’s disease mice using antisense oligonucleotides. EMBO Mol Med 2016; 8: 328–345.

163.

Morris

Maeda

Vossel

et al . The Many Faces of Tau. Neuron 2011; 70: 410–426.

164.

Kolarova

García-Sierra

Bartos

et al . Structure and pathology of tau protein in Alzheimer disease. Int J Alzheimers Dis 2012; 2012: 731526.

165.

Liu

Gong

C-X

. Tau exon 10 alternative splicing and tauopathies. Mol Neurodegener 2008; 3: 8.

166.

Nelson

Alafuzoff

Bigio

et al . Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 2012; 71: 362–381.

167.

DeVos

Miller

Schoch

et al . Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Sci Transl Med 2017; 9: pii: eaag0481.

168.

Schoch

DeVos

Miller

et al . Increased 4R-tau induces pathological changes in a human-tau mouse model. Neuron 2016; 90: 941–947.

169.

Dalakas

. Gene therapy for Duchenne muscular dystrophy: balancing good science, marginal efficacy, high emotions and excessive cost. Ther Adv Neurol Disord 2017; 10: 293–296.

170.

Gellad

Kesselheim

. Accelerated approval and expensive drugs - a challenging combination. N Engl J Med 2017; 376: 2001–2004.

171.

The Lancet Neurology. Treating rare disorders: time to act on unfair prices. The Lancet Neurology 2017; 16: 761.

172.

Zhao

Damle

Ikeda-Lee

et al . PMP22 antisense oligonucleotides reverse Charcot-Marie-Tooth disease type 1A features in rodent models. J Clin Invest. Epub ahead of print 4 December 2017. DOI: 10.1172/JCI96499.

Antisense oligonucleotides in neurological disorders

Abstract

Keywords

Introduction

Spinal muscular atrophy

Duchenne muscular dystrophy

Myotonic dystrophies

Huntington’s disease

Amyotrophic lateral sclerosis

Alzheimer’s disease

Costs, cost effectiveness and ethical implications

Conclusion

Footnotes

Funding

Conflict of interest statement

References